Welcome to the First 2016 Issue of The CLL Tribune
It’s our BIRTHDAY! One year ago today, the CLL Society website was launched and what a year it has been. Our small cadre of dedicated volunteers, and all of you readers and supporters, have brought us here in our first year:
- 170,000 plus page views on website
- 120 plus new articles written/posted
- 8 leukemia and lymphoma conferences covered and explained in patient-friendly language
- 5 alliances formed with other leukemia and lymphoma non-profits
- 4 live CLL patient education meetings hosted
- 8 CLL-specific support and education groups being launched or supported across the country
We are so appreciative of the support and feedback that we have received over the past year. We’re excited to be able to continue our efforts to address the unmet needs of CLL patients in 2016 and we hope you will continue to share your thoughts with us. What are we doing well? What could we do better? Let us know at email@example.com.
In the Reader Poll for this issue of The CLL Tribune, we would like to understand, from your perspective, what criteria are most important when making decisions about treatment, regardless of whether you have been treated or not. Please take a few minutes to complete the survey. We hope to present the findings at a symposium at the European Hematology Association (EHA) 2016 Congress this June.
If you know of someone who could benefit from learning more about CLL, please invite them to visit cllsociety.org and sign up to receive the newsletter and email alerts. Feedback and suggestions for future newsletter topics are always welcome and can be emailed to firstname.lastname@example.org .
The pace of change in CLL is not slowing. 2016 promises more important research, and we look forward to sharing and explaining all the latest news with the CLL community.
We hope you enjoy the current issue. Be on the lookout for our next issue in June!
By Anthony R Mato, MD
There is little question that the approval of kinase inhibitor therapies such as ibrutinib have revolutionized the care of patients with CLL…Read more
By Richard Furman, MD
I have not received chemotherapy for my stage 3 CLL and do not intend to do so. I am prescribed Ibrutinib at great cost to me…Read more
An Interview from the 2015 American Society of Hematology Annual Meeting with Dr. Richard Furman on the Emerging Role of Novel Agents in CLL
By Brian Koffman, MD and Richard Furman, MD
We’d like to thank the supporters of The CLL Tribune:
- Genentech/Biogen Idec
- Sunesis Pharmaceuticals
- TEVA Pharmaceuticals
- TG Therapeutics
The CLL Society does not provide medical advice or endorsements. Unless explicitly stated otherwise, all content in the CLL Tribune is the opinion or information of its author, not the CLL Society. This newsletter is for reference and educational purposes only and is not a substitute for medical advice. We do not guarantee the accuracy of any of the materials. Always contact your own doctor or other professional healthcare provider if you have any questions concerning your or your family’s health. Everyone’s circumstances are different.